

# Leveraging a legacy of leadership: Shire continues to individualize care in rare hematology

Fast Facts



## What is Hemophilia?

Hemophilia is a rare bleeding disorder in which the **blood doesn't clot normally**.<sup>1</sup>

There are an estimated **178,500** people globally living with hemophilia.<sup>2</sup>




## What is von Willebrand disease?

Von Willebrand disease is caused by a problem with a **blood protein necessary for proper clotting**.<sup>3</sup>

It is the most common bleeding disorder, affecting up to **1%** of the world's population.<sup>4</sup>

## A Series of Firsts

Transforming care for people with Hemophilia, von Willebrand disease and other bleeding disorders.



**75% TODAY**  
Around 75% percent of people with hemophilia around the world still remain undertreated<sup>13</sup>

**MOVING FORWARD**  
Shire continues to strengthen its leadership in rare bleeding disorders, building on decades of expertise in hemophilia to explore novel technologies and innovative approaches to treat people

### SOURCES:

- <http://www.nhlbi.nih.gov/health/health-topics/topics/hemophilia>
- <http://www1.wfh.org/publications/files/pdf-1627.pdf>
- <http://www.hemophilia.ca/files/All%20About%20VWD%202011%20-%20FINAL.pdf>
- <http://www.hemophilia.ca/files/All%20About%20VWD%202011%20-%20FINAL.pdf>
- Worham ST, Ortolano GA, Wenz B. A Brief History of Blood Filtration: Clot Screens, Microaggregate Removal, and Leukocyte Reduction. Pall Medical. Samuel T. Worham, Girolamo A. Ortolano, and Barry Wenz 2003 Jul;17(3):216-22.
- Curling, J., Goss, N. and Bertolini, J. (2013) The History and Development of the Plasma Protein Fractionation Industry, in Production of Plasma Proteins for Therapeutic Use (eds J. Bertolini, N. Goss and J. Curling), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9781118356807.ch1, 9.
- Spencer HT, Denning G, Gautney RE, et al. Lentiviral Vector Platform for Production of Bioengineered Recombinant Coagulation Factor VIII. Molecular Therapy. 2011;19(2):305.
- Kingdon HS, Lundblad RL. An adventure in biotechnology: the development of haemophilia A therapeutics - from whole-blood transfusion to recombinant DNA to gene therapy. Biotechnol. Appl. Biochem. 2002; 35:141-148.
- Kingdon HS, Lundblad RL. An adventure in biotechnology: the development of haemophilia A therapeutics - from whole-blood transfusion to recombinant DNA to gene therapy. Biotechnol. Appl. Biochem. 2002; 35:141-148.
- Kingdon HS, Lundblad RL. An adventure in biotechnology: the development of hemophilia A therapeutics: from whole blood transfusion to recombinant DNA to gene therapy. Biotechnol Appl Biochem. 2002;35:141-148.
- Grillberger L, Kreil TR, Nasr S, Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J. 2009;4:186-201.
- <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476065.htm>
- <https://www.hemophilia.org/About-Us/Fast-Facts>



©2017 Shire US Inc., Lexington, MA 02421.  
All rights reserved. 1-800-828-2088.  
SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates.